GYRE THERAPEUTICS, INC. 8-K/A

What Happened
Gyre Therapeutics, Inc. filed Amendment No. 1 to its Form 8‑K on July 15, 2026 to furnish financial information for Cullgen. The amendment includes Cullgen’s audited/unaudited financial statements for the three months ended March 31, 2026 and the year ended December 31, 2025, plus unaudited pro forma condensed combined financial statements showing Gyre and Cullgen on a combined basis.

Key Details

• The amendment provides Cullgen financial statements for the three months ended March 31, 2026 and for the year ended December 31, 2025.
• Includes an unaudited pro forma condensed combined balance sheet as of March 31, 2026.
• Includes unaudited pro forma condensed combined statements of operations for (a) the three months ended March 31, 2026 and (b) the year ended December 31, 2025, plus related notes.
• Filed under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).

Why It Matters
This filing gives investors the underlying financials for Cullgen and shows how Cullgen’s results would appear on a combined basis with Gyre for the stated periods. That information helps shareholders assess the financial impact of the transaction and evaluate Gyre’s recent operating performance and balance sheet position after inclusion of Cullgen.